INTRODUCTIONTranscatheter hepatic arterial chemoembolization (TACE) has become the first choice of treatment for unresectable hepatocellular carcinoma (HCC) [1][2][3][4] . Since 70%-90% of HCC patients are associated with liver cirrhosis, portal hypertension and hypersplenism, treatment of HCC is usually affected by low peripheral blood cell counts (leukcytes, platelets and red blood cells) and high incidence of hemorrhagic complications due to treatment and/or portal hypertension [5][6][7][8] . Moreover, chemotherapeutics during TACE is another cause for low peripheral blood cell counts because of myelosuppression. Partial splenic embolization (PSE), which is thought to be an effective alternative to splenomegaly [9,10] because of its milder injury and fewer complications, has been widely used in treatment of leukocytopenia and thrombocytopenia caused by splenomegaly since the report of Maddison in 1973 [11] .
MATERIALS AND METHODS
PatientsFrom December 2002 to May 2006, 50 consecutive patients with HCC associated with hypersplenism caused by liver cirrhosis and portal hypertension were enrolled in this study. The diagnosis of HCC was established on the basis of clinical laboratory data, computed tomography and biopsy. The diagnosis of hypersplenism and splenomegaly was made in the light of clinical laboratory data and computed tomography. The enrolling criteria for this study were patients with splenomegaly and thrombocytopenia (platelet count ≤ 60 × 10 9 /L) and/or leukocytopenia (leukocyte count ≤ 3.0 × 10 9 /L). Adequate supporting therapies were performed for patients having severe peritonealgia before treatment with PSE and TACE or TACE alone in order to decrease the amount of ascites. Patients meeting the above criteria were randomly assigned to either group A or group B based on the computergenerated randomization sequences. Of the 50 patients,
METHODS:Fifty patients suffering from primary HCC associated with hypersplenism caused by cirrhosis were randomly assigned to 2 groups: group A receiving PSE combined with TACE (n = 26) and group B receiving TACE alone (n = 24). Follow-up examinations included calculation of peripheral blood cells (leukcytes, platelets and red blood cells) and treatment-associated complications.
RESULTS:Prior to treatment, there was no significant difference in sex, age, Child-Pugh grade, tumor diameter, mass pathology type and peripheral blood cell counts between the 2 groups. After treatment, leukocyte and platelet counts were significantly higher in group A during the 3-mo follow-up period (P < 0.05), but lower in group B (P < 0.05). Severe complications occurred in 3 patients (11.5%) of group A and in 19 patients (79.2%) of group B (P < 0.05), and there was no significant difference in symptoms of post-embolization syndrome, including abdominal pain, fever, mild nausea and vomiting between the 2 groups (P > 0.05).CONCLUSION: PSE combined with TACE is more effective and safe than TACE alone for patients with HCC associated with hypersplenism caused by cirrhosis.